Lung cancer survival in never-smokers and exposure to residential radon: results of the LCRINS study

We aimed to evaluate lung cancer survival in never-smokers, both overall and specifically by sex, exposure to residential-radon, age, histological type, and diagnostic stage. We included lung cancer cases diagnosed in a multicentre, hospital-based, case-control-study of never-smoker patients, diagno...

Descripción completa

Detalles Bibliográficos
Autores: Casal-Mouriño, Ana, Ruano-Ravina, Alberto, Torres-Durán, María, Parente-Lamelas, Isaura, Provencio-Pulla, Mariano, Castro-Añón, Olalla, Vidal-García, Iria, Pena-Álvarez, Carolina, Abal-Arca, José, Piñeiro-Lamas, María, Fuente Merino, Ismael|||0000-0001-7757-8511, Fernández-Villar, Alberto, Abdulkader, Ihab, Valdés-Cuadrado, Luis, Barros-Dios, Juan Miguel, Pérez-Ríos, Mónica
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/31209
Acceso en línea:https://hdl.handle.net/10902/31209
Access Level:acceso abierto
Palabra clave:Lung neoplasms
Never-smokers
Indoor radon
Survival
Descripción
Sumario:We aimed to evaluate lung cancer survival in never-smokers, both overall and specifically by sex, exposure to residential-radon, age, histological type, and diagnostic stage. We included lung cancer cases diagnosed in a multicentre, hospital-based, case-control-study of never-smoker patients, diagnosed from January-2011 to March-2015 (Lung Cancer Research In Never Smokers study). 369 never-smokers (79% women; median age 71 years; 80% adenocarcinoma; 66% stage IV) were included. Median overall survival, and at one, 3 and 5 years of diagnosis was 18.3 months, 61%, 32% and 22%, respectively. Higher median survival rates were obtained for: younger age, adenocarcinoma, actionable mutations, and earlier-stage at diagnosis. Higher indoor radon showed a higher risk of death in multivariate analysis. Median lung cancer survival in never-smokers seems higher than that in ever-smokers. Patients with actionable mutations have a significantly higher survival. Higher indoor-radon exposure has a negative effect on survival